Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals ALNY
$ 149.26 -4.66%
report update icon

Quarterly report 2026-Q3
added 10-29-2026

Alnylam Pharmaceuticals Net Income | ALNY

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Alnylam Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
314 M -278 M -440 M -1.13 B -853 M -858 M -886 M -761 M -491 M -410 M -290 M -360 M -89.2 M -106 M -57.6 M -43.5 M -47.6 M -26.2 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
314 M -1.13 B -379 M

Quarterly Net Income Alnylam Pharmaceuticals

2026-Q3 2026-Q2 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2
2.17 B 164 M 112 M 293 M -72.2 M -18.3 M -83.8 M -112 M -16.9 M -65.9 M -138 M 148 M -276 M -174 M -207 M -406 M -277 M -240 M -258 M -205 M -190 M -200 M -244 M -253 M -179 M -182 M -276 M -209 M -219 M -182 M -211 M -245 M -164 M -141 M -142 M -123 M -118 M -107 M -113 M -104 M -90.1 M -103 M -90.7 M -76.8 M -71.8 M -50.8 M -21.4 M -44 M -44.1 M -251 M -32.4 M -29.7 M -18.2 M -9.01 M -62.2 M -19.5 M -13 M -11.4 M -14.3 M -13.2 M -13.8 M -16.3 M -6.93 M -9.63 M -14.6 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
2.17 B -406 M -67.7 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
1.24 B $ 1.2 4.35 % $ 54.8 M israelIsrael
Mustang Bio Mustang Bio
MBIO
-1.92 M $ 0.38 -2.31 % $ 1.87 M usaUSA
Adagene Adagene
ADAG
-17.6 M $ 1.78 20.27 % $ 105 M chinaChina
Puma Biotechnology Puma Biotechnology
PBYI
31.1 M $ 7.22 1.12 % $ 361 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
-513 M $ 18.41 2.25 % $ 3.18 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
-38.8 M $ 11.25 -0.18 % $ 4.67 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
-1.04 M $ 11.2 -1.15 % $ 101 M usaUSA
Editas Medicine Editas Medicine
EDIT
-160 M $ 1.77 -3.29 % $ 157 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
-413 M $ 29.7 -0.64 % $ 1.72 B usaUSA
Pfizer Pfizer
PFE
7.77 B $ 28.06 -1.46 % $ 159 B usaUSA
NuCana plc NuCana plc
NCNA
-29.4 M $ 0.82 -7.71 % $ 9.21 B britainBritain
Equillium Equillium
EQ
-22.4 M $ 1.1 -9.5 % $ 63 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
22.4 B $ 1.43 -1.04 % $ 81.3 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
-71.2 M $ 2.73 4.81 % $ 145 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
391 M $ 18.0 -1.77 % $ 3.03 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
-34.8 M $ 1.8 -5.26 % $ 15.5 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
-2.4 M - -7.31 % $ 49 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
149 M $ 0.66 0.38 % $ 40.5 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
-84.3 M - - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
-143 M $ 1.33 -1.48 % $ 169 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
159 M $ 33.1 0.29 % $ 1.9 B usaUSA
Ardelyx Ardelyx
ARDX
-62 M $ 3.15 -1.1 % $ 759 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
-5.3 M $ 0.41 2.22 % $ 105 M usaUSA
Alector Alector
ALEC
-143 M $ 2.56 1.17 % $ 264 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
-102 M $ 0.97 -3.11 % $ 52 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
72.1 M $ 21.81 3.27 % $ 6.83 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-33.5 M $ 4.12 1.6 % $ 789 M canadaCanada
Agenus Agenus
AGEN
-3.08 M $ 6.39 2.82 % $ 190 M usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
-34.2 M $ 6.52 -0.31 % $ 107 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
-146 M $ 11.0 -0.32 % $ 3.29 B canadaCanada
Artelo Biosciences Artelo Biosciences
ARTL
-12.9 M $ 1.5 -10.71 % $ 284 K usaUSA
Immatics N.V. Immatics N.V.
IMTX
-196 M $ 6.11 -2.94 % $ 748 M germanyGermany
Aptevo Therapeutics Aptevo Therapeutics
APVO
-26 M $ 0.45 -3.45 % $ 142 K usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-24.2 M $ 1.3 -4.41 % $ 12.9 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
-64.9 M $ 3.48 2.81 % $ 427 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
-59.5 M $ 28.47 -0.07 % $ 4.32 B usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
-21.8 M $ 0.89 -3.51 % $ 2.32 M usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
-166 M $ 3.22 7.69 % $ 268 M usaUSA
Biofrontera AG Biofrontera AG
BFRA
-13 M - -8.24 % $ 105 M germanyGermany
Pulmatrix Pulmatrix
PULM
-1.17 M $ 1.34 -2.19 % $ 4.89 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
-413 M $ 9.68 -1.07 % $ 1.05 B usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
33 M $ 12.48 3.51 % $ 8.6 B niderlandNiderland
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
-37.3 M - -6.97 % $ 657 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
-105 M $ 8.04 -4.4 % $ 374 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
98.1 M $ 29.66 1.91 % $ 1.39 B usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
57.2 B $ 14.98 1.28 % $ 12.5 B indiaIndia
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
152 M - 1.68 % $ 4.65 B chinaChina
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
4.5 B $ 945.14 -1.32 % $ 98.9 B usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-83.8 M $ 3.78 2.16 % $ 404 M usaUSA
Jaguar Health Jaguar Health
JAGX
-54 K $ 0.35 -8.69 % $ 816 K usaUSA